Sernova Biotherapeutics Inc (TSX:SVA)
0.1550
+0.0100 (6.90%)
Jun 15, 2026, 1:20 PM EST
Sernova Biotherapeutics Earnings Call Transcripts
Fiscal Year 2024
-
A regenerative medicine platform using a Cell Pouch system has shown promising results in Type 1 diabetes, with several patients achieving long-term insulin independence. Preclinical studies support the efficacy of iPSC-derived islet-like clusters, and new clinical trials are planned for 2026.